Development and validation of a predictive model to guide the use of plerixafor in pediatric population - Top-Institutions - MDSpire

Development and validation of a predictive model to guide the use of plerixafor in pediatric population

  • By

  • Bernard Sebastien

  • Peter Cheverton

  • Catherine Magnin

  • Jihane Aouni

  • Remi Castan

  • September 26, 2022

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    St. Jude Children's Research Hospital
    St. Jude Children's Research Hospital

    Memphis, TN

    Key Differentiators

    • Pediatric Hematology-Oncology
    • Stem Cell Transplantation
    • Pediatric Cancer Research

  • #2

    Dana-Farber/Boston Children's Cancer and Blood Disorders Center
    Dana-Farber/Boston Children's Cancer and Blood Disorders Center

    Boston, MA

    Key Differentiators

    • Pediatric Hematology-Oncology
    • Stem Cell Transplantation

  • #3

    Children's Hospital of Philadelphia (CHOP)
    Children's Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Hematology-Oncology
    • Stem Cell Transplantation

  • #4

    Seattle Children's Hospital / Fred Hutchinson Cancer Center
    Seattle Children's Hospital / Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Pediatric Hematology-Oncology
    • Stem Cell Transplantation
    • Cellular Therapy

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology-Oncology
    • Stem Cell Transplantation

Original Source(s)

Development and validation of a predictive model to guide the use of plerixafor in pediatric population

  • by Bernard Sebastien, Peter Cheverton, Catherine Magnin, Jihane Aouni, Remi Castan

  • September 26, 2022

Related Content

Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes

Preet M. Chaudhary, MD, PhD, discusses the repeat ranking of the USC Norris Blood and Marrow Transplant and Cell Therapy Program as one of the nation’s elite allogeneic transplant programs with the highest survival outcomes.

  • by

  • February 13, 2026

  • 12 min
Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders

Delays in Diagnosis of Hematological Cancers in Children: An Analysis of Symptom Recognition to Diagnosis Timeline and Contributing Factors at a Tertiary Hospital in Uganda